Corey Davis News
-
Valeant Pharmaceuticals International Inc., Canada’s largest drugmaker, is close to acquiring Bausch & Lomb Holdings Inc., the eye-care company owned by Warburg Pincus LLC, for about $9 billion, said a person with knowledge of the negotiations.
-
After more than 40 years in business, Elan Corp. is “just starting,” says Chief Executive Officer Kelly Martin. The Irish drugmaker may prove more rewarding for investors in its second life than in the first.
-
Biogen Idec Inc. rose to its highest value ever after the drugmaker agreed to buy partner Elan Corp.’s stake in the Tysabri multiple sclerosis medicine for $3.25 billion in cash plus future royalties.
-
Bad news for Elan Corp.’s Alzheimer’s drug is turning into good news for Biogen Idec Inc.’s takeover options.
-
DaimlerChrysler didn’t infringe patent owned by Laserfacturing Inc., a federal appeals court ruled yesterday. The dispute was over a method of welding using a laser or electron beam, covered by patent 5,595,670. The Washington-based U.S. Court of Appeals for the Federal Circuit said a Texas federal court had correctly interpreted the patent.
-
Allergan Inc. ’s Botox, the $1.4 billion drug known for smoothing facial wrinkles, will derive a dominating share of its revenue this year from therapeutic uses, such as chronic migraines, for the first time since 2006, Chief Executive Officer David Pyott said.
-
Elan Corp. fell the most in six months in New York trading on skepticism the Irish drugmaker will profitably reinvest the proceeds from selling the Tysabri multiple-sclerosis drug to Biogen Idec Inc.
-
Teva Pharmaceutical Industries Ltd. ’s multiple sclerosis pill, heir to the drugmaker’s top- selling Copaxone treatment, cut relapses of the disease less than most older injected treatments.
-
Ironwood Pharmaceuticals Inc. and Forest Laboratories Inc. won U.S. regulatory approval of their linaclotide treatment for irritable bowel syndrome with constipation.
-
Jazz Pharmaceuticals Plc climbed to its highest value ever after winning a federal judge’s support in a patent dispute over its best-selling medicine Xyrem to treat narcolepsy.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page